Jun 26, 2023 · An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen...

Jun 23, 2023 · Eli Lilly’s experimental pill for weight loss helped people lose an average of 15% of their body weight after 36 weeks on the highest dose in a midstage trial, rivaling what’s seen with...

Aug 27, 2024 · Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply...

INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.

Nov 8, 2023 · Zepbound™ (tirzepatide) injection is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30 kg/m 2), or overweight (BMI ≥ 27 kg/m 2) with at …

Apr 28, 2022 · Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study. 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions as a key secondary endpoint.

Jan 13, 2025 · Eli Lilly expects its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks told Bloomberg TV on Monday. The company is set to release key late-stage trial...

4 days ago · Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

Nov 9, 2023 · Here’s what you need to know about Lilly’s new drug. How well does Zepbound work? The active ingredient in Zepbound is tirzepatide, which mimics a hormone that helps reduce food cravings.

Jun 25, 2023 · (CNN) — Eli Lilly's experimental pill for weight loss helped people lose an average of 15% of their body weight after 36 weeks on the highest dose in a midstage trial, rivaling what's seen with...